Sarepta's 2026 Revenue Target Faces a Timing Test as Cohort 8 Data Moves to 2027

The 2026 target rests on a real commercial base

The immediate support for Sarepta's 2026 story is revenue that is already showing up. In the second quarter, the company reported $328.7 million in net product revenue, driven by $230.6 million of PMO sales and $98.1 million of ELEVIDYS sales. That gives the bull case a tangible starting point rather than relying only on distant hopes.

Why the debate exists

The bear case is mostly about recent direction. ELEVIDYS sales fell from $102.0 million in the first quarter of 2026 to $98.1 million in the second quarter, while PMO sales were relatively flat. If that trend continues, a large 2026 sales target can look ambitious before the recovery is visible in the numbers.

That is the core timing issue. Sarepta is still advancing Cohort 8 of the ENDEAVOR study, but outside coverage now points to Q1 2027 for the next major ELEVIDYS data window from this cohort. For investors looking to ELEVIDYS for the next step-change in growth, that means a longer wait.

Why Cohort 8 matters more than the headline range

The bigger question is not whether Sarepta can defend a 2026 revenue range. It is whether the company can clear the next major clinical and commercial hurdle for ELEVIDYS: safer use in non-ambulatory patients. That is what Cohort 8 of ENDEAVOR is designed to address, which is why the timing shift matters more than a simple headline forecast.

Non-ambulatory patients are the key expansion path

Sarepta is pursuing sirolimus pretreatment as part of an enhanced safety approach to help make ELEVIDYS available again in the non-ambulatory population, and the study is enrolling approximately 25 participants in the U.S. who are non-ambulatory. If successful, this would matter beyond a single data readout because it could broaden the treatable population.

The dosing design shows how the company is trying to de-risk that expansion. Participants receive 14 days of peri-infusion sirolimus dosing before ELEVIDYS, with treatment continuing for 12 weeks after administration. The primary endpoints are the incidence of acute liver injury and ELEVIDYS-dystrophin expression at 12 weeks. In practical terms, the key question is whether the enhanced immunosuppression reduces liver injury without erasing the biological signal.

Clinical benefit is easier to see in ambulatory patients

There is already evidence that ELEVIDYS can matter functionally in children who still have ambulatory capacity. In 8- and 9-year-olds in EMBARK Part 2, the therapy produced a 4.75-point NSAA benefit, along with improvements in time-to-rise and 10-meter walk/run versus an external control cohort. Those results help explain why access and safety in more advanced disease are such important next steps.

The harder question is whether gene therapy can be delivered more safely once ambulation is lost. That is why Cohort 8 is the real swing factor: it has to show not only biological activity, but a tolerable safety profile in a higher-risk group.

What matters in the next few quarters

The delay pushes the payoff out, but it does not remove the need to watch near-term execution. Investors should focus less on the final answer alone and more on whether Sarepta is still holding the 2026 story together in the meantime.

A useful baseline is the first-quarter commercial run rate: Q1 ELEVIDYS at $102.0 million and PMO at $228.6 million. If that base remains steady, patience through the wait for Q1 2027 data becomes easier to justify.

Signals that would support the bull case

• Steady PMO and ELEVIDYS sales rather than continued softness.
• Visible trial execution, including enrollment progress and no major safety setbacks in Cohort 8.
• Any credible signal that the enhanced immunosuppression regimen is improving the safety profile without eliminating biological activity.

Signals that would weaken the thesis

• FurtherELEVIDYS declines without signs of stabilization.
• Slow enrollment or unclear motion in Cohort 8.
• Evidence that the regimen does not meaningfully improve safety in non-ambulatory patients.

The near term is less about celebrating a revenue target and more about testing whether Sarepta can keep execution on track while waiting for a later pivotal data moment.